Insurers Say They ‘Can’t Afford’ Ozempic and Zepbound. What the Data on Healthier Patients and Cost Savings Actually Shows.

In the first half of 2026, a growing number of employers and insurers announced they were scaling back or ending coverage for GLP-1 medications like Zepbound and Wegovy when used for weight loss. HeadLines framed it as simple arithmetic: these drugs cost too much, and plans could no longer afford them. The reality is more layered, and the emerging data on what happens to patients’ health and downstream medical costs when people stay on these medications adds important context that the “can’t afford it” narrative often leaves out.

The Coverage Pullback Is Real and Concentrated on Weight Loss

Across 2025 and into 2026, multiple major players restricted access specifically for the obesity indication. Blue Cross Blue Shield of Massachusetts ended coverage for GLP-1 weight-loss drugs for many small-group employers starting January 2026. Harvard Pilgrim and Blue Cross Blue Shield of Michigan took similar steps. CVS Caremark removed Zepbound from formulary coverage in mid-2025. California’s Medi-Cal program stopped covering Wegovy, Zepbound, and Saxenda for weight loss or weight-related conditions for adults effective January 1, 2026, while preserving access for Type 2 diabetes.

GoodRx tracking showed tens of millions of commercially insured Americans losing coverage for these specific products. For many patients, the change arrived via prior authorization denials or outright exclusion notices rather than gradual tightening.

What Insurance Companies Are Seeing on Their Spreadsheets

The dominant explanation from benefits managers and insurers is straightforward budget pressure. GLP-1 medications moved from niche to top-line cost driver with extraordinary speed. In multiple employer surveys and analyses released in 2025 and early 2026, GLP-1s accounted for 10–20% of total pharmacy spend in plans that covered them, with year-over-year spending growth in some cases exceeding 50%. For self-insured employers, the combination of high list prices (often $1,000+ per month before rebates) and rapid uptake among eligible employees created immediate and visible hits to pharmacy budgets.

Even after substantial rebates and discounts that bring net prices down significantly (often estimated in the $500–800/month range depending on the plan and negotiations), the sheer volume of prescriptions made these drugs impossible to ignore in annual renewals. Employee turnover added another complication: many employers invest in the high upfront cost only to see the member leave for another job before longer-term health improvements fully materialize in lower claims.

The Other Side of the Ledger: What Happens When Patients Stay on Therapy

Clinical trials have long shown that GLP-1 receptor agonists produce substantial weight loss, better glycemic control, and meaningful reductions in cardiovascular risk markers. Real-world data is now catching up on the economic side.

A major January 2026 analysis by Aon examined medical and pharmacy claims from more than 50 million commercial lives, including 192,000 GLP-1 users between July 2022 and March 2025. The findings provide some of the clearest employer-relevant numbers yet:

6–9 ptsHow much slower overall medical costs grew among adherent GLP-1 users, per Aon’s January 2026 analysis of claims from more than 50 million commercially insured Americans.

The same analysis found additional signals of broader health impact. Female GLP-1 users experienced approximately 50% lower incidence of ovarian cancer and 14% lower incidence of breast cancer compared with matched non-users over the study period, along with a 47% reduction in hospitalizations for major adverse cardiovascular events.

These are not small signals. They align with the cardiovascular outcome trials (SELECT for semaglutide, SURPASS/SURMOUNT programs for tirzepatide) and suggest that when patients remain on therapy, real medical cost offsets begin to appear within the 18–30 month window that many large self-insured employers can actually measure.

Why the Savings Haven’t Stopped the Coverage Cuts

If patients are getting meaningfully healthier, why are so many plans walking away? Several structural factors explain the gap between the Aon-type findings and the coverage decisions. One of the most important is timing.

• Front-end costs, back-end savings. The drug expense hits immediately and every month. Avoided heart attacks, strokes, diabetes complications, and hospitalizations accrue over years. Many employer plan horizons and employee tenure windows are shorter than the payback period.
• Adherence is everything and it’s hard. Real-world persistence on GLP-1s is often well below the high-adherence thresholds where the strongest cost-growth reductions appear. Discontinuation rates of 50% or higher within the first year are commonly reported; when people stop, many of the metabolic and inflammatory benefits reverse relatively quickly.
• Workforce turnover. A self-insured employer that pays for two years of therapy may never see the downstream savings if the employee moves to a different plan.
• Current net pricing still high relative to demonstrated short-term ROI. Independent cost-effectiveness modeling published in JAMA Health Forum in 2025 found that tirzepatide and semaglutide generate substantial lifetime health gains (averting tens of thousands of diabetes and cardiovascular disease cases per 100,000 eligible adults) but carry incremental cost-effectiveness ratios of roughly $197,000 and $468,000 per QALY gained at current net prices, well above common U.S. willingness-to-pay thresholds without significant further discounts.

What This Means Going Forward

The 2026 coverage reversals are not primarily a rejection of the science that GLP-1 medications improve health markers and can reduce certain costly complications. They are a reflection of how American healthcare financing currently handles expensive chronic-disease therapies: heavy emphasis on near-term budget impact, limited ability to capture long-term returns across different payers, and high sensitivity to any single drug class that moves the needle on total pharmacy spend.

Patients who stay on therapy and achieve sustained weight loss and cardiometabolic improvement are, on average, consuming fewer medical resources over time than they otherwise would. That signal is now visible in large claims datasets. The challenge is aligning the payment model with that reality through outcomes-based contracts, longer-term risk sharing, better adherence support programs, or pricing that reflects demonstrated value at scale.

For now, the “can’t afford it” headlines capture a genuine short-term constraint for many plans. The fuller story is that some patients are getting meaningfully healthier on these drugs, and the data increasingly show measurable downstream effects on medical cost trajectories, but only when adherence is high and the time horizon is long enough for those effects to compound. Bridging that gap remains one of the central policy and business challenges in obesity and diabetes care.

The same question, asked of a different corner of medicine: New Dental Tools: Longer-Lasting Care or a More Expensive Tool Belt?.